See more : Platinum Capital Limited (PMC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Adicet Bio, Inc. (ACET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adicet Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- iRobot Corporation (I8R.DE) Income Statement Analysis – Financial Results
- Tisdale Clean Energy Corp. (TCEFF) Income Statement Analysis – Financial Results
- EssilorLuxottica Société anonyme (EL.PA) Income Statement Analysis – Financial Results
- Global Li-Ion Graphite Corp. (GBBGF) Income Statement Analysis – Financial Results
- AGI Greenpac Limited (AGI.BO) Income Statement Analysis – Financial Results
Adicet Bio, Inc. (ACET)
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 24.99M | 9.73M | 17.90M | 995.00K | 8.18M | 558.52M | 546.95M | 510.18M | 499.69M | 499.69M | 444.39M | 412.43M | 346.63M | 322.65M | 359.59M |
| Cost of Revenue | 6.10M | 5.01M | 0.00 | 0.00 | 125.00K | 80.00K | 5.00K | 411.52M | 395.48M | 401.42M | 401.42M | 362.36M | 346.59M | 292.48M | 267.03M | 292.29M |
| Gross Profit | -6.10M | 19.98M | 9.73M | 17.90M | 870.00K | 8.10M | 558.52M | 135.43M | 114.70M | 98.27M | 98.27M | 82.03M | 65.84M | 54.16M | 55.62M | 67.31M |
| Gross Profit Ratio | 0.00% | 79.96% | 100.00% | 100.00% | 87.44% | 99.02% | 100.00% | 24.76% | 22.48% | 19.67% | 19.67% | 18.46% | 15.96% | 15.62% | 17.24% | 18.72% |
| Research & Development | 106.04M | 71.25M | 48.94M | 34.33M | 23.69M | 14.72M | 16.84M | 5.94M | 5.22M | 2.83M | 0.00 | 0.00 | 0.00 | 0.00 | 153.00K | 506.00K |
| General & Administrative | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 76.82M | 73.16M | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -74.78M | -73.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 2.04M | 1.00K | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Other Expenses | 19.46M | -919.00K | -606.00K | -953.00K | 2.33M | 4.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 70.43M | 63.86M | 63.86M | 56.67M | 49.29M | 44.72M | 43.73M | 45.93M |
| Cost & Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 465.91M | 465.27M | 465.27M | 419.02M | 395.88M | 337.19M | 310.75M | 338.21M |
| Interest Income | 9.95M | 3.76M | 91.00K | 785.00K | 938.00K | 543.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 80.00K | 176.00K | 134.00K | 0.00 | 0.00 | 7.00M | 3.95M | 2.10M | 2.12M | 2.12M | 2.63M | 1.57M | 230.00K | 98.00K | 145.00K |
| Depreciation & Amortization | 6.10M | 5.01M | 4.07M | 1.95M | 1.24M | 80.00K | 5.00K | 11.85M | 8.09M | 6.94M | 6.94M | 6.94M | 5.50M | 2.80M | 1.87M | 2.38M |
| EBITDA | -136.54M | -64.70M | -60.41M | -37.41M | -26.88M | -13.74M | -33.77M | -1.00K | 54.87M | 43.62M | 43.62M | 34.31M | 24.03M | 13.23M | 14.70M | 24.71M |
| EBITDA Ratio | 0.00% | -278.95% | -636.67% | -219.85% | -2,701.61% | -105.93% | -3.38% | 0.00% | 10.75% | 8.73% | 8.73% | 7.72% | 5.83% | 3.82% | 4.55% | 6.87% |
| Operating Income | -152.04M | -72.55M | -61.43M | -39.19M | -31.39M | -14.96M | -18.88M | -1.00K | 44.27M | 34.42M | 34.42M | 25.37M | 16.55M | 9.44M | 11.89M | 21.38M |
| Operating Income Ratio | 0.00% | -290.32% | -631.38% | -218.91% | -3,154.57% | -182.91% | -3.38% | 0.00% | 8.68% | 6.89% | 6.89% | 5.71% | 4.01% | 2.72% | 3.69% | 5.94% |
| Total Other Income/Expenses | 9.38M | 2.76M | -691.00K | -302.00K | 3.27M | 5.08M | -14.90M | 0.00 | 402.00K | 134.00K | 134.00K | -626.00K | 412.00K | 765.00K | 839.00K | 812.00K |
| Income Before Tax | -142.66M | -69.79M | -62.12M | -39.49M | -28.12M | -9.89M | -33.78M | -1.00K | 44.67M | 34.55M | 34.55M | 24.74M | 16.96M | 10.20M | 12.73M | 22.19M |
| Income Before Tax Ratio | 0.00% | -279.27% | -638.48% | -220.59% | -2,826.03% | -120.87% | -6.05% | 0.00% | 8.76% | 6.91% | 6.91% | 5.57% | 4.11% | 2.94% | 3.95% | 6.17% |
| Income Tax Expense | 0.00 | -2.76M | -125.00K | -2.82M | 19.00K | -589.00K | 19.09M | 20.38M | 15.67M | 12.22M | 12.22M | 7.76M | 7.99M | 3.62M | 4.10M | 8.72M |
| Net Income | -142.66M | -67.03M | -62.00M | -36.68M | -28.14M | -9.30M | -33.78M | -1.00K | 29.00M | 22.33M | 22.33M | 16.98M | 8.97M | 6.58M | 8.63M | 13.47M |
| Net Income Ratio | 0.00% | -268.22% | -637.19% | -204.87% | -2,827.94% | -113.67% | -6.05% | 0.00% | 5.68% | 4.47% | 4.47% | 3.82% | 2.17% | 1.90% | 2.67% | 3.75% |
| EPS | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.26 | 0.00 | 1.18 | 0.94 | 0.94 | 0.73 | 0.40 | 0.30 | 0.40 | 0.63 |
| EPS Diluted | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.25 | 0.00 | 1.16 | 0.93 | 0.93 | 0.72 | 0.39 | 0.30 | 0.39 | 0.62 |
| Weighted Avg Shares Out | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.77M | 28.05M | 24.50M | 23.67M | 23.67M | 23.26M | 22.67M | 21.86M | 21.43M | 21.30M |
| Weighted Avg Shares Out (Dil) | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.97M | 28.05M | 24.99M | 24.02M | 24.02M | 23.46M | 22.84M | 22.07M | 21.86M | 21.70M |
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter...
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will...
3 High-Risk Stocks That Could Pay Off in the Millions
High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market's appetite for risk continues to grow.
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on February 29, 2024....
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
7 Top-Tier Penny Stocks for a Smart Bet
Penny stocks are heating up as the S&P 500 hits new highs, signaling opportunity. With the S&P 500 posting new highs multiple times in the past few months and prospects of lower interest rates, the stage is set for potentially...
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will...
Source: https://incomestatements.info
Category: Stock Reports